Phase 1 Cystic Fibrosis Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You must be willing and able to read, sign, and follow the study's consent forms and instructions
- You must be 18 years old or older when you sign the consent form
- You must have a confirmed diagnosis of cystic fibrosis (CF), shown by symptoms plus either a sweat chloride test result above 60 mmol/L or two copies of a CF-causing gene mutation
- Your CF must be considered stable by the study doctor at the time of joining
- Your lung function (measured by a breathing test called FEV1) must be between 40% and 90% of what is normal for your age, sex, and height
- Your blood oxygen level must be 92% or higher while breathing normal room air
Who may not be able to join:
- You started a new long-term treatment (such as a CFTR modulator, saltwater inhaler, or inhaled antibiotic) or changed an existing one within the past 28 days (not including digestive enzyme supplements)
- You were hospitalised, had a lung infection, a CF flare-up, or another significant illness in the 14 days before starting the study
- You were treated for a specific bacterial infection called Mycobacterium abscessus within the past 3 months, or had more than two serious lung flare-ups with a history of Burkholderia cenocepacia infection in the past 6 months
- You have taken part in another clinical trial or received an experimental treatment within the past 30 days (or longer, depending on the treatment)
- You have had, or are on a waiting list for, an organ transplant (such as a lung or liver transplant)
- You have a condition — such as uncontrolled asthma, a weakened immune system, or a history of substance use disorder — that the study doctor believes could affect your safety or ability to complete the study
- You have had an active cold sore (oral herpes) infection in the 30 days before starting the study
- You are currently pregnant or breastfeeding
- You are unwilling to follow the birth control requirements set out in the study plan
- You have abnormal blood test results at your screening visit that the study doctor believes could affect the study results
- You have a known allergy or sensitivity to inhaled glycerol
- The study doctor believes you are unlikely to follow the study requirements
- (For bronchoscopy participants only) You are unable to tolerate a bronchoscopy procedure (a camera examination of the airways) in the opinion of the study doctor (confirm with trial site)
- (For one specific group only — Cohort 4) You are not eligible for, cannot tolerate, or do not benefit from CFTR modulator therapy (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 412-586-5830
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
To evaluate safety and tolerability of KB407 based upon assessment of adverse events (frequency, severity, relatedness), and changes from baseline in physical examinations, vital signs, ECG, and clinical laboratory test results
Can't join this trial?
Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.